A Phase I Study of CC-98633 CAR T-Cell Therapy in People with Recurrent or Persistent Multiple Myeloma

Share
Print

Full Title

A Phase 1, Multicenter, Open-Label Study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed and/or Refractory Multiple Myeloma

Purpose

CAR T-cell therapy is a type of immunotherapy. With CAR T-cell therapy, white blood cells called T cells are removed from the patient, altered in the laboratory to recognize a protein on the patient’s cancer cells, multiplied to larger numbers, and returned to the patient to find and destroy cancer cells. The treatment is made from the modified T cells.

In this study, researchers are assessing a CAR T-cell therapy called CC-98633 for patients with multiple myeloma that has come back or continued to grow despite treatment. CC-98633 recognizes a protein called BCMA on the surface of multiple myeloma cells and can destroy those cells. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has come back or continued to grow despite at least three prior regimens of therapy, including an autologous stem cell transplant.
  • Patients should recover from the serious side effects of prior therapies before entering the study.
  • Patients may not have previously had CAR T-cell therapy or any treatment that targets BCMA.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Sham Mailankody at 212-639-2131.

Protocol

20-310

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators